tamoxifen
Astrazeneca
['ovarian', 'bcsm']
asstra trial looking at adding 2 yrs ovarian suppression (os) to tamoxifen for women that remained premeno after chemo f/u over 100 months dfs benefit w/ os: hr 0.67, 80 to 85% dfs majority of events distant #asco22 #bcsm 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.